摘要
急性T淋巴细胞白血病（T-ALL）患者约50%~60%会出现由NOTCH 1基因突变导致的NOTCH 1信号通路异常激活,针对NOTCH 1信号通路的分子靶向治疗,可克服传统化疗药物的非靶向性,有助于解决化疗药物对正常细胞和机体损伤较大的问题。本文综述NOTCH 1信号通路及靶向治疗T-ALL的国内外研究进展。
About 50%-60% ofT-cell acute lymphoblastic leukemia （T-ALL） shows the abnormal activation of NOTCH 1 signaling pathway due to mutation of NOTCH 1 gene. So the targeted therapy against NOTCH 1 signaling pathway has clinical significance, especially for chemotherapy refractory patients. It can solve the damage problems on normal cells and organs in the patients who received traditional chemotherapy. This review describes the function of NOTCH 1 signaling pathway and the development of targeted therapy in T-ALL.
出处
《世界临床药物》
CAS
2016年第11期770-775,共6页
World Clinical Drug
基金
上海市科学技术委员会重大项目子课题(编号:14411950603)
